JP2008540683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540683A5 JP2008540683A5 JP2008512566A JP2008512566A JP2008540683A5 JP 2008540683 A5 JP2008540683 A5 JP 2008540683A5 JP 2008512566 A JP2008512566 A JP 2008512566A JP 2008512566 A JP2008512566 A JP 2008512566A JP 2008540683 A5 JP2008540683 A5 JP 2008540683A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- hydroxymethyl
- oxolan
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- -1 6-[((3R) oxolan-3-yl) amino] -2- {4- [4- (trifluoromethyl) phenyl] (1,2,3-triazolyl)} purin-9-yl Chemical group 0.000 claims 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004258 purin-2-yl group Chemical group [H]N1C2=NC(*)=NC([H])=C2N([H])C1([H])[H] 0.000 claims 2
- JWFPXVFJPXMSJB-ZOICRDBHSA-N (3r,4s,5r)-2-[2-(5-benzyl-2h-triazol-4-yl)-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N1C2=NC(C=3C(=NNN=3)CC=3C=CC=CC=3)=NC(NC3CCCC3)=C2N=C1 JWFPXVFJPXMSJB-ZOICRDBHSA-N 0.000 claims 1
- OEBYTPORZBFSSD-ITAOHXQZSA-N (3r,4s,5r)-2-[6-(cyclopentylamino)-2-(2h-tetrazol-5-yl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N1C2=NC(C=3NN=NN=3)=NC(NC3CCCC3)=C2N=C1 OEBYTPORZBFSSD-ITAOHXQZSA-N 0.000 claims 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- JPDMSXOVYWRIBS-IKYDMHQPSA-N 1-[6-(cyclohexylamino)-9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]triazole-4-carboxylic acid Chemical compound C1CCC(CC1)NC2=C3C(=NC(=N2)N4C=C(N=N4)C(=O)O)N(C=N3)C5[C@@H]([C@@H]([C@H](O5)CO)O)O JPDMSXOVYWRIBS-IKYDMHQPSA-N 0.000 claims 1
- NTJFCRDCFITCLR-XWHOZGLOSA-N 1-[6-(cyclopentylamino)-9-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-n-methyltriazole-4-carboxamide Chemical compound N1=NC(C(=O)NC)=CN1C1=NC(NC2CCCC2)=C(N=CN2C3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 NTJFCRDCFITCLR-XWHOZGLOSA-N 0.000 claims 1
- AMZRGLCQCSEUIU-VGWNDNRCSA-N 1-[6-(cyclopentylamino)-9-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]triazole-4-carboxamide Chemical compound N1=NC(C(=O)N)=CN1C1=NC(NC2CCCC2)=C(N=CN2C3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 AMZRGLCQCSEUIU-VGWNDNRCSA-N 0.000 claims 1
- DFMYMVNQKRLFPQ-AARXTDBFSA-N 1-[6-(cyclopentylamino)-9-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]triazole-4-carboxylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N1C2=NC(N3N=NC(=C3)C(O)=O)=NC(NC3CCCC3)=C2N=C1 DFMYMVNQKRLFPQ-AARXTDBFSA-N 0.000 claims 1
- 102000009346 Adenosine receptors Human genes 0.000 claims 1
- 108050000203 Adenosine receptors Proteins 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- SSYDTHANSGMJTP-UHFFFAOYSA-N oxolane-3,4-diol Chemical compound OC1COCC1O SSYDTHANSGMJTP-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68326305P | 2005-05-19 | 2005-05-19 | |
| US60/683,263 | 2005-05-19 | ||
| PCT/US2006/019599 WO2006125190A1 (en) | 2005-05-19 | 2006-05-19 | A1 adenosine receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540683A JP2008540683A (ja) | 2008-11-20 |
| JP2008540683A5 true JP2008540683A5 (enExample) | 2009-06-25 |
| JP5042996B2 JP5042996B2 (ja) | 2012-10-03 |
Family
ID=37022210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512566A Expired - Fee Related JP5042996B2 (ja) | 2005-05-19 | 2006-05-19 | Ａ１アデノシンレセプターアゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7381714B2 (enExample) |
| EP (1) | EP1883646A1 (enExample) |
| JP (1) | JP5042996B2 (enExample) |
| CA (1) | CA2609051A1 (enExample) |
| WO (1) | WO2006125190A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140041965A (ko) * | 2007-05-17 | 2014-04-04 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법 |
| WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| AU2009231978C1 (en) | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| CN101712709A (zh) * | 2008-10-06 | 2010-05-26 | 中国医学科学院药物研究所 | 三乙酰基-3-羟基苯基腺苷及其调血脂的用途 |
| CZ2009298A3 (cs) * | 2009-05-14 | 2010-11-24 | Univerzita Palackého v Olomouci | Substituované 6-benzylaminopurin ribosidy, jejich použití a farmaceutický prípravek tyto slouceniny obsahující |
| US8414852B1 (en) * | 2011-11-21 | 2013-04-09 | Fluor Technologies Corporation | Prevention of nitro-amine formation in carbon dioxide absorption processes |
| US9040498B2 (en) | 2012-07-06 | 2015-05-26 | Research Foundation Of The City University Of New York | 1,2,3-Triazolyl purine derivatives |
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| JP6306607B2 (ja) | 2012-12-21 | 2018-04-04 | ケモセントリックス，インコーポレイティド | ジアゾールアミド |
| US9422267B2 (en) | 2012-12-26 | 2016-08-23 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| IL261998B2 (en) | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| AU2019276662A1 (en) * | 2018-05-26 | 2020-12-17 | Primetime Life Sciences, Llc | Compounds and methods for modulation of G-protein-coupled receptors |
| EP4541803A4 (en) * | 2022-06-17 | 2025-10-01 | Shanghai Senhui Medicine Co Ltd | CYCLOPENTYLADENOSINE DERIVATIVE AND ITS PHARMACEUTICAL USE |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| JP3517127B2 (ja) * | 1998-10-19 | 2004-04-05 | 矢崎総業株式会社 | 自動切断圧着装置 |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| IL149470A0 (en) | 1999-11-23 | 2002-11-10 | Aderis Pharmaceuticals Inc | Pharmaceutical compositions containing carboxamidoadenosine derivatives |
| US20030078232A1 (en) * | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| US7262176B2 (en) | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
| WO2004011010A1 (en) * | 2002-07-29 | 2004-02-05 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
-
2006
- 2006-05-19 US US11/437,774 patent/US7381714B2/en not_active Expired - Lifetime
- 2006-05-19 WO PCT/US2006/019599 patent/WO2006125190A1/en not_active Ceased
- 2006-05-19 EP EP06770753A patent/EP1883646A1/en not_active Withdrawn
- 2006-05-19 JP JP2008512566A patent/JP5042996B2/ja not_active Expired - Fee Related
- 2006-05-19 CA CA002609051A patent/CA2609051A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9963480B2 (en) | Nucleoside phosphoramidate compound and use thereof | |
| EP2678332B1 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
| TWI649305B (zh) | 脲衍生物、或其藥理學上所容許之鹽 | |
| HK1044953A1 (zh) | C-吡唑a2a受體激動劑 | |
| JP2024532518A (ja) | Ｇｌｐ１ｒアゴニストとしての新規アリールエーテル置換複素環式化合物 | |
| JP6746614B2 (ja) | ウレア誘導体、またはその薬理学的に許容される塩 | |
| HK1044952B (zh) | N-吡唑a2a受体激动剂 | |
| CA2476683A1 (en) | Partial and full agonists of a1 adenosine receptors | |
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2005527502A5 (enExample) | ||
| CN101056879A (zh) | 作为a3和a1腺苷受体激动剂的嘌呤衍生物 | |
| CN108349904B (zh) | Ppar激动剂、化合物、药物组合物及其使用方法 | |
| EP2699557B1 (en) | 3-(oxazol-2-yl-ethoxy)- and 3-(thiazol-2-yl-ethoxy)-benzamide derivatives as anti-bacterial agents | |
| EP2785707B1 (en) | Novel 2h-indazoles as ep2 receptor antagonists | |
| JP2008514668A5 (enExample) | ||
| CN1894225A (zh) | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 | |
| EP2308838A1 (en) | Nitrogen-containing aromatic heterocyclyl compound | |
| WO2010104024A1 (ja) | プロスタグランジンd合成酵素を阻害するピペラジン化合物 | |
| RU2009127781A (ru) | Производные аденозина в качестве частичных и полных агонистов а1 аденозиновых рецепторов | |
| CN109265380A (zh) | 取代的丙-2-烯-1-酮化合物及其药物组合物 | |
| CN1671399A (zh) | 利用a2a受体激动剂的心肌灌注显像 | |
| DK2059503T3 (en) | Aminopyrazole derivatives, processes for their preparation, and compositions containing these derivatives for the prevention or treatment of ischemic diseases | |
| JP2008540685A5 (enExample) | ||
| US7381714B2 (en) | A1 adenosine receptor agonists | |
| JP2006516641A5 (enExample) |